Related references
Note: Only part of the references are listed.Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series
Mattia Fonderico et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Anna He et al.
LANCET NEUROLOGY (2020)
Initial high-efficacy disease-modifying therapy in multiple sclerosis A nationwide cohort study
Mathias Due Buron et al.
NEUROLOGY (2020)
Cerebrospinal fluid oligoclonal IgM test in routine practice: Comparison with quantitative assessment of intrathecal IgM synthesis
David Zeman et al.
CLINICA CHIMICA ACTA (2020)
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
Katharine Harding et al.
JAMA NEUROLOGY (2019)
Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis
Christiane Gasperi et al.
JAMA NEUROLOGY (2019)
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
Daniel Ontaneda et al.
LANCET NEUROLOGY (2019)
Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis
Catherina Pfuhl et al.
NEUROLOGY (2019)
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
J. William L. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Unraveling treatment response in multiple sclerosis A clinical and MRI challenge
Claudio Gasperini et al.
NEUROLOGY (2019)
Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
Jessica Frau et al.
JOURNAL OF NEUROLOGY (2018)
Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients
Andre Huss et al.
ANNALS OF NEUROLOGY (2018)
Clinical usefulness of prognostic biomarkers in optic neuritis
A. Tejeda-Velarde et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Oscar Fernandez
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results
Serkan Ozakbas et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2017)
Defining secondary progressive multiple sclerosis
Johannes Lorscheider et al.
BRAIN (2016)
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
Emer Fogarty et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice
M. Espino et al.
CLINICA CHIMICA ACTA (2015)
Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome
Diana Ferraro et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Intrathecal oligoclonal IgG synthesis in multiple sclerosis
Axel Petzold
JOURNAL OF NEUROIMMUNOLOGY (2013)
Response to the letter of Villar et al. 'Quantitative and qualitative IgM analysis in CSF'
Hansotto Reiber et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual
Laurence Durante et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Comment on the article by Stauch et al. 'Intrathecal IgM synthesis in paediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis'
L. M. Villar et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes
Maria Jose Magraner et al.
NEURORADIOLOGY (2012)
Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis
C. Stauch et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM
Patrizia Sola et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands
I. Bosca et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
A multifactorial prognostic index in multiple sclerosis - Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease
Jessica Mandrioli et al.
JOURNAL OF NEUROLOGY (2008)
Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis
M. Thangarajh et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Influence of oligoclonal IgM specificity in multiple sclerosis disease course
L. M. Villar et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis
Peter J. H. Jongen et al.
EUROPEAN NEUROLOGY (2007)
Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis
P. Perini et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)
Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis
LM Villar et al.
ANNALS OF NEUROLOGY (2003)
Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS
LM Villar et al.
NEUROLOGY (2002)
Intrathecal IgM synthesis in neurologic diseases:: Relationship with disability in MS
LM Villar et al.
NEUROLOGY (2002)
A sensitive and reproducible method for the detection of oligoclonal IgM bands
LM Villar et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Share Paper
